Business Updates and Financial Highlights from Cellectis
NEW YORK – Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS), a company at the forefront of biotechnology, has shared important updates and financial results for the nine-month period ending September 30, 2024. The company is dedicated to developing groundbreaking cell and gene therapies utilizing its innovative gene editing platform.
Recent Developments
During this quarter, Cellectis made significant strides in its developments. The enrollment for the UCART22 and UCART20x22 programs is actively continuing, and the company plans to present the Phase 1 datasets and a strategic plan for late-stage development in 2025. Cellectis is also engaged in ongoing research and development activities under a partnership with AstraZeneca, focusing on three key programs: an allogeneic CAR T for hematological malignancies, an allogeneic CAR T for solid tumors, and a novel in vivo gene therapy targeting a genetic disorder.
Leadership Updates
In an effort to bolster its clinical programs, Cellectis appointed Dr. Adrian Kilcoyne as Chief Medical Officer. Dr. Kilcoyne is noted for his extensive experience and leadership in drug development within the cell therapy realm, which comes at a crucial time as Cellectis advances its clinical trials.
Financial Position
As of September 30, 2024, Cellectis reported a robust cash position of $264 million, with a cash runway projected to extend into 2027. This solid financial footing allows the company to continue its critical work in developing innovative therapies for patients in need. The significant cash influx includes $140 million from AstraZeneca as part of their recent equity investment and $16 million received from the European Investment Bank.
Pipelines and Development Focus
Cellectis is focusing primarily on two clinical programs: UCART22 for treating relapsed or refractory B-cell acute lymphoblastic leukemia through its BALLI-01 study, and UCART20x22 for treating relapsed or refractory B-cell non-Hodgkin lymphoma in the NATHALI-01 study. The commitment to these studies reflects Cellectis' strategic priorities to enhance its pipeline and bring promising therapies to market.
Collaborations and Partnerships
Cellectis' collaboration with AstraZeneca not only facilitates sustaining research initiatives but also aims at developing new cell and gene therapy candidate products. Under the terms of their joint research agreement, AstraZeneca is leveraging Cellectis’ proprietary gene editing technologies to explore up to ten candidates. The partnership signifies Cellectis’ commitment to innovation and addressing unmet medical needs.
Recent Scientific Publication
On September 3, 2024, Cellectis published a groundbreaking article in Science Advances that investigates TALEN®-edited MUC1 CAR T-cells as a potential treatment for advanced-stage triple-negative breast cancer (TNBC). This publication illustrates the company’s continued efforts in utilizing its gene editing platform to discover effective treatments for challenging cancer types.
Financial Results Overview
In analyzing the financial results, total revenues for the nine months ended September 30, 2024, reached $34.1 million, a notable increase from $7.2 million in the same period in 2023. The increase in revenues can primarily be attributed to the recognition of revenue from development milestones and the ongoing collaboration with AstraZeneca.
Research and Development Expenses
R&D expenses for the period ended September 30, 2024, amounted to $69.7 million compared to $62.7 million in 2023, reflecting Cellectis’ heightened investment in research initiatives and manufacturing activities. The continuous commitment to R&D underscores the company's dedication to lead advancements in the biotechnology space.
Conclusion
Cellectis continues to demonstrate robust operational progress alongside substantial financial backing. With a clear focus on advancing its clinical programs and expanding strategic partnerships, Cellectis remains well-positioned to deliver innovative therapies to patients who have yet to see satisfactory treatment options.
Frequently Asked Questions
What is Cellectis known for?
Cellectis is a biotechnology company specializing in gene editing and developing innovative cell and gene therapies.
What are the major programs Cellectis is currently working on?
Cellectis is actively working on UCART22 for leukemia treatment and UCART20x22 for non-Hodgkin lymphoma, with plans to present clinical data in 2025.
How has Cellectis' financial position changed?
As of September 30, 2024, Cellectis reported a cash position of $264 million, a significant increase allowing for continued operational funding into 2027.
Who is the Chief Medical Officer of Cellectis?
Dr. Adrian Kilcoyne has been appointed as the Chief Medical Officer, bringing extensive expertise in drug development to the role.
What partnerships does Cellectis have?
Cellectis has a strategic partnership with AstraZeneca for developing joint research initiatives focused on CAR-T therapies and gene therapies.
